期刊文献+
共找到6篇文章
< 1 >
每页显示 20 50 100
苦参素治疗老年性慢性丙型肝炎伴合并症临床分析 被引量:5
1
作者 李玲 王淑兰 《传染病信息》 2006年第1期41-41,48,共2页
目的观察苦参素治疗老年性慢性丙型肝炎合并高血压、糖尿病、白细胞减少及65岁以上患者的效果。方法治疗组给予苦参素600mg,每日静点1次。对照组给予一般保肝药,疗程3个月。结果治疗结束时,治疗组ALT复常率94.9%,对照组36.8%,2组显著差... 目的观察苦参素治疗老年性慢性丙型肝炎合并高血压、糖尿病、白细胞减少及65岁以上患者的效果。方法治疗组给予苦参素600mg,每日静点1次。对照组给予一般保肝药,疗程3个月。结果治疗结束时,治疗组ALT复常率94.9%,对照组36.8%,2组显著差异(P<0.05),HCVRNA治疗组转阴55.6%,对照组5.3%,2组显著差异(P<0.01)。结论苦参素是老年性慢性丙型肝炎伴合并症状患者的新希望。 展开更多
关键词 苦参素 老年性慢性丙型肝炎合并症
下载PDF
天晴复欣治疗老年慢性丙型肝炎伴合并症临床分析 被引量:3
2
作者 刘威 黄鑫 王淑兰 《中国冶金工业医学杂志》 2005年第6期676-677,共2页
关键词 慢性丙型肝炎 天晴复欣 合并症 老年性 临床分析 治疗 结果报告 苦参素 抗病毒
下载PDF
苦参素治疗老年性慢性丙型肝炎临床分析
3
作者 任建勋 徐广林 《中外医学研究》 2009年第6期102-102,共1页
目的观察苦参素治疗老年性慢性丙型肝炎合并高血压、糖尿病、白细胞减少及65岁以上患者的临床效果。方法治疗组给予苦参素0.6,每日一次,静脉点滴。对照组给予一般保肝药,疗程3个月。结果疗程结束,治疗组PLT复常率91.3%,对照组33... 目的观察苦参素治疗老年性慢性丙型肝炎合并高血压、糖尿病、白细胞减少及65岁以上患者的临床效果。方法治疗组给予苦参素0.6,每日一次,静脉点滴。对照组给予一般保肝药,疗程3个月。结果疗程结束,治疗组PLT复常率91.3%,对照组33.3%。两组有显著差异(P〈0.01)。HCV—RNA治疗组转阴52.2%,对照组8.3%,两组有显著差异(P〈0.01)。结论苦参素是老年性慢性丙型肝炎伴合并症患者的新希望。 展开更多
关键词 苦参素 老年性慢性丙型肝炎 临床分析 治疗方法
下载PDF
慢性肾衰竭维持性血液透析合并丙型肝炎患者血清心肌肌钙蛋白的变化
4
作者 戎其飞 赵卫红 +3 位作者 王笑云 苏恩本 毛慧娟 杨志健 《中国血液净化》 2003年第10期554-557,共4页
目的 观察慢性肾衰竭 (CRF)维持性血液透析合并丙型肝炎患者血清心肌肌钙蛋白 (cTnI)的异常变化。方法 应用双抗夹心酶联免疫吸附法 (ELISA)检测 115例维持性血液透析患者分为丙型肝炎阳性组 70例和阴性组 4 5例及 6 4例正常人的血清c... 目的 观察慢性肾衰竭 (CRF)维持性血液透析合并丙型肝炎患者血清心肌肌钙蛋白 (cTnI)的异常变化。方法 应用双抗夹心酶联免疫吸附法 (ELISA)检测 115例维持性血液透析患者分为丙型肝炎阳性组 70例和阴性组 4 5例及 6 4例正常人的血清cTnI。结果 慢性肾衰竭组血清cTnI阳性率为 17.4 % ,其中丙型肝炎阳性组为 2 0 % ,丙型肝炎阴性组为 13.3% ,丙型肝炎阳性组cTnI水平显著高于丙型肝炎阴性组 (P <0 .0 1)。结论 慢性肾衰竭血液透析患者的心肌损伤明显高于正常人群 ,合并丙型肝炎可加重慢性肾衰竭血液透析患者的心肌损伤 。 展开更多
关键词 慢性肾衰竭 维持性血液透析 合并症 丙型肝炎 血清 心肌肌钙蛋白
下载PDF
32例老年人肺炎临床治疗体会
5
作者 陈秉尧 张新颖 《中国社区医师(医学专业)》 2010年第22期71-71,共1页
关键词 老年人肺炎 临床治疗 慢性支气管炎 肝肾功能减退 老年性疾病 发病时间 动脉硬化 合并症
下载PDF
Glucose intolerance in Chinese patients with chronic hepatitis C 被引量:5
6
作者 Liang-KungChen Shinn-JangHwang +3 位作者 Shih-TzerTsai Jiing-ChyuanLuo Shou-DongLee Full-YoungChang 《World Journal of Gastroenterology》 SCIE CAS CSCD 2003年第3期505-508,共4页
AIM: To investigate the prevalence and the risk factors of glucose intolerance in Chinese patients with chronic hepatitis C and to evaluate the relationship between interferon (IFN)treatment and glucose intolerance in... AIM: To investigate the prevalence and the risk factors of glucose intolerance in Chinese patients with chronic hepatitis C and to evaluate the relationship between interferon (IFN)treatment and glucose intolerance in these patients.METHODS: Prospective cross-sectional study was done to evaluate the prevalence of glucose intolerance in Chinese patients with chronic hepatitis C virus (HCV) infection from the outpatient clinic of Department of Family Medicine, Taipei Veterans General Hospital. Chronic hepatitis C was defined as persistent presence of anti-HCV and persistent elevation of liver transaminase for at least 1.5 folds for at least 6 months. Moreover, patients were further categorized into normal fasting glucose and glucose intolerance (diabetes mellitus (DM) and impaired fasting glucose) according to the diagnostic criteria of American Diabetic Association. RESULTS: Totally, 359 Chinese patients with chronic hepatitis C were enrolled (212 males and 147 females, mean age=58.1±13.0 years). One hundred and twenty-three patients (34.3 %) had various forms of IFN treatment. One hundred and twenty-five patients (34.6 %)had glucose intolerance, including 99 patients (27.6 %) with DM and 26 patients (7.0 %) with impaired fasting glucose.Tn comparison with those with normal fasting glucose levels,patients with chronic hepatitis C with glucose intolerance were significantly older, had a significantly higher body mass index, and they were more likely to suffer from obesity, to have family history of diabetes and to have had previous IFN treatment. Stepwise multivariate logistic regression revealed significantly that age ≥ 57 years, obesity,previous history of IFN treatment and the presence of family history of diabetes were independent risk factors associated with the presence of glucose intolerance in chronic hepatitis C patients.CONCLUSION: In conclusion, 34.6 % of Chinese patients with chronic hepatitis C had glucose intolerance. Chronic hepatitis C patients who were older in age, obese, had previous IFN treatment history and had family history of diabetes were prone to develop glucose intolerance. To our knowledge, this is the first population-based report to confirm that interferon treatment to be an independent risk factor to develop glucose intolerance. 展开更多
关键词 葡萄糖不耐受 慢性丙型肝炎 干扰素 糖尿病 临床研究 合并症
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部